A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 2, 2014, Pages 363-371

  Tolcher, Anthony W ^a   Rodrigueza, Wendi V ^b   Rasco, Drew W ^a   Patnaik, Amita ^a   Papadopoulos, Kyriakos P ^a   Amaya, Alex ^a   Moore, Timothy D ^c   Gaylor, Shari K ^b   Bisgaier, Charles L ^b   Sooch, Mina P ^b   Woolliscroft, Michael J ^b   Messmann, Richard A ^b  

^a South Texas Accelerated Research Therapeutics (START)   (United States)

^b ProNAi Therapeutics Inc   (United States)

^c Mid Ohio Oncology Hematology   (United States)

Author keywords

BCL2; Deoxyribonucleic acid inhibitor; DNAi; Liposome; Phase I; PNT2258

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; PNT 2258; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BREAST ADENOCARCINOMA; CLINICAL ARTICLE; COLON ADENOCARCINOMA; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; FLANK PAIN; HEAD AND NECK CARCINOMA; HUMAN; INFUSION RELATED REACTION; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SARCOMA; SIDE EFFECT; SOLID TUMOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; DNA; FEMALE; HUMANS; LIPOSOMES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; TREATMENT OUTCOME;

EID: 84896049687     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2361-0     Document Type: Article

References (45)

1. (2012) PK analysis for a phase 1 study of PNT2258 in patients with advanced solid tumors. Internal document (ProNAi Therapeutics) conducted by VEEDA Clinical Research, Brussels, Belgium
2. Adams JM, Cory S (2007) Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 19(5):488-496. doi:10.1016/j.coi.2007. 05.004 (Pubitemid 47487452)
3. Cory S, Adams JM (2005) Killing cancer cells by flipping the Bcl-2/Bax switch. Cancer Cell 8(1):5-6. doi:10.1016/j.ccr.2005.06.012 (Pubitemid 40991809)
4. Davids MS, Letai A (2012) Targeting the B-cell lymphoma/leukemia 2 family in cancer. J Clin Oncol 30(25):3127-3135. doi:10.1200/JCO.2011.37.0981
5. The SMARTICLES® technology: enabling systemic DNA therapeutics. http://pharmalicensing.com/public/outlicensing/view/12158/the-smarticles- technology-enabling-systemic-dna-therapeutics
6. Adami RC, Seth S, Harvie P, Johns R, Fam R, Fosnaugh K, Zhu T, Farber K, McCutcheon M, Goodman TT, Liu Y, Chen Y, Kwang E, Templin MV, Severson G, Brown T, Vaish N, Chen F, Charmley P, Polisky B, Houston ME Jr (2011) An amino acid-based amphoteric liposomal delivery system for systemic administration of siRNA. Mol Ther J Am Soc Gene Ther 19(6):1141-1151. doi:10.1038/mt.2011.56
7. Seth S, Johns R, Templin MV (2012) Delivery and biodistribution of siRNA for cancer therapy: challenges and future prospects. Ther deliv 3(2):245-261
8. Rodrigueza WV, Mohammad R, McGovern JP, Wick MJ, Rasco D, Tolcher AW, Bisgaier CL (2012) Effect of PNT2258 combinations with docetaxel, dacarbazine, or vemurafenib on the A375 melanoma xenograft. In: AACR 103rd Annual Meeting 2012, Chicago, IL, 31 Mar-4 Apr, 2012
9. (2010) PNT100 Expression in preclinical murine samples. Internal document (ProNAi Therapeutics)
10. Nicolaou AE (2009) Mode of action of PNT100 (trans: Department P). Internal document (ProNAi Therapeutics) conducted by Novosom AG
11. Thurman RE, Rynes E, Humbert R, Vierstra J, Maurano MT, Haugen E, Sheffield NC, Stergachis AB, Wang H, Vernot B, Garg K, John S, Sandstrom R, Bates D, Boatman L, Canfield TK, Diegel M, Dunn D, Ebersol AK, Frum T, Giste E, Johnson AK, Johnson EM, Kutyavin T, Lajoie B, Lee BK, Lee K, London D, Lotakis D, Neph S, Neri F, Nguyen ED, Qu H, Reynolds AP, Roach V, Safi A, Sanchez ME, Sanyal A, Shafer A, Simon JM, Song L, Vong S, Weaver M, Yan Y, Zhang Z, Zhang Z, Lenhard B, Tewari M, Dorschner MO, Hansen RS, Navas PA, Stamatoyannopoulos G, Iyer VR, Lieb JD, Sunyaev SR, Akey JM, Sabo PJ, Kaul R, Furey TS, Dekker J, Crawford GE, Stamatoyannopoulos JA (2012) The accessible chromatin landscape of the human genome. Nature 489(7414):75-82. doi:10.1038/nature11232
12. Schmitz R, Renne C, Rosenquist R, Tinguely M, Distler V, Menestrina F, Lestani M, Stankovic T, Austen B, Brauninger A, Hansmann ML, Kuppers R (2005) Insights into the multistep transformation process of lymphomas: IgH-associated translocations and tumor suppressor gene mutations in clonally related composite Hodgkin's and non-Hodgkin's lymphomas. Leukemia 19(8):1452-1458. doi:10.1038/sj.leu.2403841 (Pubitemid 41136341)
13. Technical Report 2-ProNAi Research Protocol 236: efficacy evaluation of PNT2258 stored frozen and stored refrigerated in WSU-DLCL2 xenograft bearing CB-17 SCID mice in combination with rituximab. Kalamazoo, MI
14. (2010) A Repeat-Dose Safety Pharmacology Study (with evaluation of cardiovascular, respiratory, and central nervous systems) of PNT2258 Administered to Cynomolgus Monkeys by Intravenous Infusion. ProNAi Therapeutics report number CRL (Charles River Labs) LLF00001
15. (2010) A 4-Week (2-Cycle) Intravenous Toxicity and Pharmacokinetic/Tissue Distribution Study of PNT2258 in Rats. ProNAi Therapeutics report number MPI (MPI Research) 1208-002
16. Legakis HC, Tran P, Rodrigueza WV, Bisgaier C (2012) Development and validation of a hybridization-ligation assay for the quantitative measurement of PNT100, the oligonucleotide component present in liposomal formulation PNT2258, in human plasma. Paper presented at the 14th annual TIDES conference: oligonucleotide and peptide therapeutics from research through commercialization, Las Vegas
17. (2010) A 4-Week (2-Cycle) Intravenous Toxicity and Pharmacokinetic/Tissue Distribution Study of PNT2258 and an Active Analogue in Cynomolgus Monkeys. ProNAi Therapeutics report number MPI (MPI Research) 1208-003
18. Senior JH (1987) Fate and behavior of liposomes in vivo: a review of controlling factors. Crit Rev Ther Drug Carrier Syst 3(2):123-193
19. http://www.clinicaltrials.gov/ct2/show/NCT01191775?term=PNT2258&rank= 1
20. http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf
21. http://www.eortc.be/recist/
22. Analysis of pharmacokinetic data CRL 345764. Clinical Reference Laboratory, Lenexa, Kansas 66215 USA
23. Seth S, Matsui Y, Fosnaugh K, Liu Y, Vaish N, Adami R, Harvie P, Johns R, Severson G, Brown T, Takagi A, Bell S, Chen Y, Chen F, Zhu T, Fam R, Maciagiewicz I, Kwang E, McCutcheon M, Farber K, Charmley P, Houston ME Jr, So A, Templin MV, Polisky B (2011) RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer. Mol Ther J Am Soc Gene Ther 19(5):928-935. doi:10.1038/mt.2011.21
24. Ackler S, Mitten MJ, Chen J, Clarin J, Foster K, Jin S, Phillips DC, Schlessinger S, Wang B, Leverson JD, Boghaert ER (2012) Navitoclax (ABT 263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumors in vivo. Br J Pharmacol. doi:10.1111/j.1476-5381.2012.02048.x
25. Chen J, Jin S, Abraham V, Huang X, Liu B, Mitten MJ, Nimmer P, Lin X, Smith M, Shen Y, Shoemaker AR, Tahir SK, Zhang H, Ackler SL, Rosenberg SH, Maecker H, Sampath D, Leverson JD, Tse C, Elmore SW (2011) The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 10(12):2340-2349. doi:10.1158/1535-7163.MCT-11-0415
26. Mattoo AR, Fitzgerald DJ (2012) Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines. Int J Cancer. doi:10.1002/ijc.27732
27. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18(11):3163-3169. doi:10.1158/1078-0432.CCR-11-3090
28. Sakuma Y, Tsunezumi J, Nakamura Y, Yoshihara M, Matsukuma S, Koizume S, Miyagi Y (2011) ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis. Oncol Rep 25(3):661-667. doi:10.3892/or2010.1123
29. Schoenwaelder SM, Jackson SP (2012) Bcl-xL-inhibitory BH3 mimetics (ABT-737 or ABT-263) and the modulation of cytosolic calcium flux and platelet function. Blood 119(5):1320-1321. doi:10.1182/blood-2011-10-387399 (author reply 1321-1322)
30. Shi J, Zhou Y, Huang HC, Mitchison TJ (2011) Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res 71(13):4518-4526. doi:10.1158/0008-5472.CAN-10-4336
31. Tan N, Malek M, Zha J, Yue P, Kassees R, Berry L, Fairbrother WJ, Sampath D, Belmont LD (2011) Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res 17(6):1394-1404. doi:10.1158/1078-0432. CCR-10-2353
32. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, Roberts L, Tahir SK, Xiao Y, Yang X, Zhang H, Fesik S, Rosenberg SH, Elmore SW (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68(9):3421-3428. doi:10.1158/0008-5472.CAN-07-5836
33. Vogler M, Dickens D, Dyer MJ, Owen A, Pirmohamed M, Cohen GM (2011) The B-cell lymphoma 2 (BCL2)-inhibitors, ABT-737 and ABT-263, are substrates for P-glycoprotein. Biochem Biophys Res Commun 408(2):344-349. doi:10.1016/j.bbrc. 2011.04.043
34. Walensky LD (2012) From mitochondrial biology to magic bullet: navitoclax disarms BCL-2 in chronic lymphocytic leukemia. J Clin Oncol 30(5):554-557. doi:10.1200/JCO.2011.37.9339
35. Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11(12):1149-1159. doi:10.1016/S1470-2045(10) 70261-8
36. Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ, Belmont LD (2012) Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol Cancer Ther 11(4):1026-1035. doi:10.1158/1535-7163.MCT-11-0693
37. Davids MS, Letai A (2013) ABT-199: taking dead aim at BCL-2. Cancer Cell 23(2):139-141. doi:10.1016/j.ccr.2013.01.018
38. Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM (2011) Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29(7):909-916. doi:10.1200/JCO.2010.31.6208
39. Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, Carney DA, He SZ, Huang DC, Xiong H, Cui Y, Busman TA, McKeegan EM, Krivoshik AP, Enschede SH, Humerickhouse R (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30(5):488-496. doi:10.1200/JCO.2011.34.7898
40. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park CM, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202-208. doi:10.1038/nm.3048
41. Basit F, Cristofanon S, Fulda S (2013) Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ. doi:10.1038/cdd.2013.45
42. Herbst RS, Frankel SR (2004) Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 10(12 Pt 2):4245s-4248s. doi:10.1158/1078-0432.CCR- 040018 (Pubitemid 38812455)
43. Rasco DW, Patnaik A, Amaya A, Gaylor S, Moore T, Izbicka E, Streeper R, Rodrigueza W, Messmann R, Tolcher A (2012) A study of PNT2258 (DNA-targeted Blocker of BCL2 Expression) in patients with advanced solid tumors. Eur J Cancer 48(Suppl 6):191. doi:10.1016/S0959-8049(12)72417-6
44. Rasco DW, Papadopoulos K, Wick M, Amaya A, Izbicka E, Streeper R, Louden C, Woolliscroft M, Sooch M, Messmann RA, Rodrigueza WV (2013) Effect of PNT2258, an anti-BCL2 DNA-interference drug, on tumor growth and immunological markers in mice and humans. In: American association of cancer research annual meeting, Washington, DC, 18 January 2013
45. Lightfoot HL, Hall J (2012) Target mRNA inhibition by oligonucleotide drugs in man. Nucleic Acids Res 40(21):10585-10595. doi:10.1093/nar/gks861